Under the Consideration of Analysts: Novavax Inc (NVAX)

Lloyd Doyle
January 31, 2018

For the current year the company's revenue estimates are $28.78 Million compared to low analyst estimates of $26.8 Million and high estimates of $31 Million according to the prediction of 7 analysts.

The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 83.08%, and has a solid year to date (YTD) performance of 72.58% which means that the stock is constantly adding to its value from the previous fiscal year end price.

A number of brokerages have issued reports on NVAX. S&P Equity Research lowered their target price on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th.

Novavax, Inc. (NASDAQ:NVAX) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. BidaskClub raised Novavax from a "hold" rating to a "buy" rating in a research report on Saturday, December 30th.

The 6 analysts offering 12-month price forecasts for Novavax Inc have a median target of 2.00, with a high estimate of 10.00 and a low estimate of 1.50. For Novavax, Inc. (NASDAQ:NVAX), Stochastic %D value stayed at 76.02% for the last 9 days. If a firm has enough quick assets to cover its total current liabilities, the firm will be able to pay off its obligations without having to sell off any long-term or capital assets.

Taking a broader look at the analyst consensus, according to 6 analysts Novavax Inc (NASDAQ:NVAX)'s price will reach at $3.25 during 52 weeks. The company's beta value stood at 2.82.


EPS in next five years is expected to touch 0.00% while EPS growth in past 5 year was -43.40% along with sales growth of 0.90% in the last five years. Analysts have a mean recommendation of 2.6 on this stock.

In other news, insider Stanley C. Erck purchased 100,000 shares of the company's stock in a transaction on Thursday, November 9th. The shares were acquired at an average cost of $1.13 per share, with a total value of $113,000.00. The company has a market capitalization of $683.99 Million. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. As of today, the company has a SMA200 (200-day simple moving average) of 83.08 Percent.

Several hedge funds and other institutional investors have recently modified their holdings of NVAX. Schwab Charles Investment Management Inc. lifted its position in shares of Novavax by 39.4% during the 2nd quarter. The company's forward price to earnings ratio for next fiscal year is 0. Earnings surprises can have a huge impact on a company's stock price. Northern Trust Corp grew its position in shares of Novavax by 2.8% in the second quarter.

The company announced its last quarter financial performance results on 11/07/2017. JPMorgan Chase & Co. increased its position in Novavax by 40.1% in the second quarter.

Novavax Inc (NASDAQ:NVAX) as of current trade, has shown weekly performance of 0% which was maintained at 69.84% in one month period. Alliancebernstein L.P. now owns 425,701 shares of the biopharmaceutical company's stock valued at $490,000 after buying an additional 121,200 shares during the last quarter. They see Novavax, Inc. "(NVAX)" was originally published by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and global copyright & trademark law.

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. The Company operates through developing recombinant vaccines segment.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER